Clinical trials: Myocardial Fibrosis
Type 2 Diabetes Mellitus, Myocardial Fibrosis
Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2
There is an unmet need for Cardiovascular Disease (CVD) risk reduction in patients with Type 2 Diabetes. In recent trials there has been promising findings of more effective glucose management and reductions in overall CVD events…
- Conditions
- Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation
- Trial name
- NCT03782259
- Testing
- dapagliflozin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Washington
Myocardial Fibrosis, Hypertrophic Cardiomyopathy
Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is the most common genetic cardiomyopathy and remains the leading cause of sudden cardiac death in young people and an important cause of heart failure symptoms and death at any age.
- Trial name
- NCT00879060
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center